Immune checkpoint inhibitor therapy

Immune checkpoint inhibitor therapy is a relatively new treatment for certain cancers which result in immune system-mediated destruction of tumor cells.

Immune checkpoint inhibitors act through a unique mechanism of action when compared with those of conventional chemotherapeutic agents. They target cell surface receptors:

• cytotoxic T-lymphocyte antigen-4
• programmed cell death protein 1
• programmed cell death ligand 1 (PD-L1)

Complications

• immune checkpoint inhibitor therapy-related pneumonitis
• immune-related endocrinopathies 
  • immune-related hypophysitis 
• sarcoid-like lymphadenopathy and granulomatosis
  • pembrolizumab induced sarcoid like reaction
• colitis
• hepatitis
• hyperprogression, an atypical response of paradoxical accelerated growth of tumor

Siehe auch:

• Neuritis nervi optici
• Autoimmunhypophysitis
• Hashimoto-Thyreoiditis
• Adrenalitis

und weiter:

• Autoimmunadrenalitis